Immunovant stops lupus development and H.C. Wainwright keeps Buy rating on Immunovant stock

Published on 10/16/2026 at 04:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IMVT-1402 missed its primary endpoint in a 57-patient trial on September 23, 2026. Immunovant stock retains a USD 41.00 target from H.C. Wainwright.

Pipeline after lupus decision

On September 23, 2026, Immunovant ended one program after a 57-patient study missed its primary endpoint.
H.C. Wainwright maintained a Buy rating and a USD 41.00 target on September 24, 2026.
Immunovant reported its first-quarter results on August 6, 2026, and its next report is scheduled for November 18, 2026.

IMVT, US45258J1025, Illustration mit AI erstellt.

Immunovant (ISIN US45258J1025) stopped developing IMVT-1402 for cutaneous lupus after a 57-patient proof-of-concept study missed its primary endpoint on September 23, 2026, according to Immunovant. H.C. Wainwright maintained a Buy rating and a USD 41.00 price target on September 24, 2026, according to Investing.com.

One trial ends, five continue

The setback is specific to cutaneous lupus, but it removes one of six disclosed indications for IMVT-1402. The company said development continues in Graves' disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and Sjogren's disease.

The trial's primary endpoint measured the percentage change in the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity score after 12 weeks. The result did not reach statistical significance, although Immunovant reported numerical trends across several endpoints and a favorable safety and tolerability profile.

What does the trial change?

The numbers leave the pipeline broad but raise the importance of evidence from the five remaining indications. Investors are weighing a failed 12-week endpoint against the company's stated plan to keep other clinical timelines on track.

Three dated milestones

On August 6, 2026, Immunovant reported results for the quarter ended June 30, 2026, marking its first quarter of fiscal 2027. On September 23, 2026, it disclosed the 57-patient cutaneous lupus result and the program decision. On September 24, 2026, H.C. Wainwright maintained its Buy rating and USD 41.00 target.

The next reporting date

Immunovant's next earnings report is scheduled for November 18, 2026, according to Investing.com. That date will give investors the next formal update on cash use, clinical progress and development priorities.

Pipeline breadth remains central

Immunovant is a clinical-stage biotechnology company developing therapies for autoimmune diseases. The lupus decision narrows one path, while five other indications remain part of the IMVT-1402 development plan.